(3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(3aR,6aR)-5-[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-6-oxo-3,3a,4,6a-tetrahydro-2H-pyrrolo[2,3-c]pyrrol-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid | 143267-34-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(3aR,6aR)-5-[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-6-oxo-3,3a,4,6a-tetrahydro-2H-pyrrolo[2,3-c]pyrrol-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid
• CAS: 143267-34-9
• 化学式: C₄₈H₇₀N₁₀O₁₁S
• 分子量: 995.21
• InChiKey: RXPYHERBFPILFA-JMVZBETESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  70
• 可旋转键数：
  29
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  364
• 氢给体数：
  10
• 氢受体数：
  14

反应信息

• 作为产物：
  描述：

  FMOC-O-叔丁基-L-丝氨酸五氟苯酯 、 N-芴甲氧羰基-L-苯丙氨酸五氟苯酯 、 Nα-Fmoc-L-Asn-OPfp 、 <3aR(3aα,6aα,2'S^*)>-1-<(9-fluorenylmethoxy)carbonyl>-octahydro-α-(2-methylpropyl)-6-oxopyrrolo<3,4-b>pyrrole-5-acetic acid pentafluorophenyl ester 、 alkaline earth salt of/the/ methylsulfuric acid 生成 (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-1-[(3aR,6aR)-5-[(2S)-1-[[(2S)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-6-oxo-3,3a,4,6a-tetrahydro-2H-pyrrolo[2,3-c]pyrrol-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-[[(2S)-2,6-diaminohexanoyl]amino]-4-oxobutanoic acid
  参考文献：
  名称：

  Conformationally constrained tachykinin analogs: potent and highly selective neurokinin NK-2 receptor agonists

  摘要：

  The design and synthesis of potent and seleCtive neurokinin NK-2 receptor agonists 12 (GR64349) and 31 are described, together with structure-activity relationships for related analogues. Compound 12 (EC50 = 3.7 nM at NK-2 receptors in the rat colon; selectivity > 1000- and > 300-fold with respect to NK-1 and NK-3 receptors. respectively) was derived by incorporation of a Gly-Leu gamma-lactam conformational constraint into the C-terminal region of the neurokinin A. octapeptide analogue [Lys3]-NKA(3-10). Compound 31 (EC50 = 15 nM in rat colon) contains a novel fused-bicyclic constraint at the corresponding site in the substance P hexapeptide analogue [Ava6]-SP(6-11).

  DOI：

  10.1021/jm00100a027

文献信息

• Conformationally constrained tachykinin analogs: potent and highly selective neurokinin NK-2 receptor agonists
  作者：Martyn J. Deal、Russell M. Hagan、Simon J. Ireland、Christopher C. Jordan、Andrew B. McElroy、Barry Porter、Barry C. Ross、Michaela Stephens-Smith、Peter Ward

  DOI：10.1021/jm00100a027

  日期：1992.10

  The design and synthesis of potent and seleCtive neurokinin NK-2 receptor agonists 12 (GR64349) and 31 are described, together with structure-activity relationships for related analogues. Compound 12 (EC50 = 3.7 nM at NK-2 receptors in the rat colon; selectivity > 1000- and > 300-fold with respect to NK-1 and NK-3 receptors. respectively) was derived by incorporation of a Gly-Leu gamma-lactam conformational constraint into the C-terminal region of the neurokinin A. octapeptide analogue [Lys3]-NKA(3-10). Compound 31 (EC50 = 15 nM in rat colon) contains a novel fused-bicyclic constraint at the corresponding site in the substance P hexapeptide analogue [Ava6]-SP(6-11).